Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Carcinoma, Non-Small-Cell Lung 47Melanoma 23Neoplasm Metastasis 19Neoplasms 18Squamous Cell Carcinoma of Head and Neck 17Lung Neoplasms 13Skin Neoplasms 12Recurrence 10Head and Neck Neoplasms 10Carcinoma, Renal Cell 9Prostatic Neoplasms 8Ovarian Neoplasms 8Colorectal Neoplasms 8Carcinoma, Squamous Cell 8Breast Neoplasms 8Urinary Bladder Neoplasms 7Carcinoma, Merkel Cell 7Triple Negative Breast Neoplasms 6Colonic Neoplasms 6Carcinoma, Basal Cell 6Carcinoma 6Adenocarcinoma 6Uterine Cervical Neoplasms 5Sarcoma 5Pancreatic Neoplasms 5Glioblastoma 5Stomach Neoplasms 4Multiple Myeloma 4Mouth Neoplasms 4Fallopian Tube Neoplasms 4

Interventions

Cisplatin 123Gemcitabine 70Radiotherapy, Intensity-Modulated 56toripalimab 39Capecitabine 36Fluorouracil 33Docetaxel 32Radiotherapy 24camrelizumab 23Drug Therapy 20nimotuzumab 18spartalizumab 13pembrolizumab 13nedaplatin 12apatinib 11Chemoradiotherapy 11tislelizumab 10sintilimab 10Nivolumab 10Magnetic Resonance Spectroscopy 10Induction Chemotherapy 10Immune Checkpoint Inhibitors 10Specimen Handling 9Cetuximab 9Carboplatin 9endostar protein 8Paclitaxel 8Bevacizumab 8anlotinib 7Radiation 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Nasopharyngeal Carcinoma × cemiplimab × Clear all
NCT06980038 2026-06-01

Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer

National Cancer Institute (NCI)

Phase 2 Recruiting
44 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Laryngeal Neoplasms, Mouth Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡